期刊文献+

替吉奥联合顺铂治疗晚期胃癌近期疗效观察 被引量:1

Recent Efficacy of S-1 Combined with Cisplatin in the Treatment of Patients with Advanced Gastric Carcinoma
下载PDF
导出
摘要 目的观察替吉奥胶囊(S-1)联合顺铂治疗晚期胃癌的近期疗效和毒副反应。方法初治和复治的晚期胃癌53例,替吉奥胶囊每天80mg/m2,2次/d,口服14d,停药7d;顺铂75mg/ml,d1~3静脉滴注,21d为1个周期,2周期后评价疗效。结果总有效率为67.9%(36/53),主要毒副反应为胃肠道反应,Ⅲ~Ⅳ度的白细胞减少占13.2%(7/53)。结论替吉奥胶囊联合顺铂方案治疗晚期胃癌是有效、安全的。 Objective To evaluate the efficacy and toxicity of the combination of S-1 and cisplation in the treatment of patients with advanced gastric carcinoma. Methods 53 patients with advanced gastric carcinoma were treated with S-1 plus c isplatin, 80 mg·m2. d·S-1 was given orally for 14 days, twice one day, drug withdrawal for 7 days; 75 mg/m~ cisplatin was intravenously injected for 1 - 3 days, 21 d was a cycle, the efficacy was evaluated after 2 cycles. Results The total effective rate was 67.9% (36/53), the main side effects were gas- trointestinal reactions, the decrease of grade Ⅲ-Ⅳ leukcocytes accounted for 13.2% (7/53). Conclusion S-1 combined with cisplatin for the treatment of advanced gastric carcinoma is effective and safe.
出处 《临床医学工程》 2011年第3期357-358,共2页 Clinical Medicine & Engineering
关键词 晚期胃癌 联合化疗 替吉奥胶囊 顺铂 Advanced gastric carcinoma Combined chemotherapy S-1 Cisplatin
  • 相关文献

参考文献6

  • 1Tsuburaya A, Sakamoto J, Morita S, et d. A randomized phase Ⅲ trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial [J] . Jpn J Clin Oncol, 2005, 35 (11) : 672- 675.
  • 2Iwase H, Shimada M, Nakamura M, et al. A pilot study of TS-1 combined with eisplatin in patients with advanced gastric cancer [J] . Can To Kagaku Ryoho, 2002, 29 (9) : 1575-1582.
  • 3Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1) : a review [J] . Oneologist, 2002, 7 (4) : 288-323.
  • 4Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapen potential [J] . Invest New drugs, 2000, 18 (4) : 331-342.
  • 5Kadokawa Y, Sonoda K, Nakajima S, et ol. Advanced gastric cancer in an elderly woman showing histcpathologic CR after a course of S-1 and CDDP combination therapy [J] . Gan To Kagaku Ryoho, 2010, 37 (4) : 711-713.
  • 6秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268

二级参考文献17

  • 1钱军,秦叔逵,梅静峰,陈映霞,邵志坚,何泽明.奥沙利铂联合卡培他滨二线治疗晚期胃癌的临床观察[J].中华肿瘤杂志,2004,26(12):746-748. 被引量:60
  • 2Moiseyenko VM,Ajani JA,Tjulandin SA,et al.Final results of a randomized controlled phase Ⅲ trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F)to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2005,23:Abstract 4002.
  • 3Al-Batran S,Hartmann J,Probst S,et al.A randomized phase Ⅲ trial in patients with advanced adenocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil,leucovorin and oxaliplatin (FLO) versus fluorouracil,leucovorin and cisplatin (FLP)[J].J Clin Onc,Proc Am Soc Clin Oncol,2006,24:Abstract 4016.
  • 4Bugat R.Irinotecan in the treatment of gastric cancer[J].Ann Oncol,2003,14(Suppl 2):37 -40.
  • 5Bouche O,Raoul JL,Bonnetain F,et al.Randomized multicenter phase Ⅱ trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),LV5FU2 plus cisplatin,or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer:a Federation Francophone de Cancerologie Digestive Group Study-FFCD 9803[ J].J Clin Oncol,2004,22 (21):4319-4328.
  • 6Fazio N,Zampino G,Nol F,et al.Irinotecan combined with in fusional 5-fluorouracil and folinic acid (folfiri) in patients with metastatic gastric cancer resistant to cisplatin-containing chemo therapy[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4146a.
  • 7Peeters M,Van Laethem JL,Baert F,et al.Phase Ⅱ study of irinotecan+ 5FU/FA for patients with previously treated ad vanced gastric cancer[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4076a.
  • 8Bamias A,Papamichael D,Syrigos K,et al.Phase Ⅱ study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer[J].J Chemother,2003,15(3):275 -281.
  • 9Giuliani F,Maiello E,Molica S,et al.Irinotecan (CPT-11)and Mitomycin-C (MMC) as second-line treatment in advanced gastric cancer patients.A phase Ⅱ study of the Gruppo Oncologico dell Italia Meridionale (GOIM)[J].J Clin Onc,Proc Am Soc Clin Oncol,2004,22:Abstract 4235.
  • 10Shah M A,Ramanathan RK,Ilson D,et al.Final results of a multicenter phase Ⅱ study of irinotecan (CPT),cisplatin (CIS),and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma[ J ].J Clin Onc,Proc Am Soc Clin Oncol,2006,24 (18S):Abstract 4020.

共引文献267

同被引文献11

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部